Pfizer unveils its oral SARS-CoV-2 inhibitor
Bethany Halford
Abstract
Drugmaker Pfizer presented its oral COVID-19 antiviral clinical candidate PF-07321332 last week at ACS Spring 2021. The compound, which is currently in Phase 1 clinical trials, is the first orally ...
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakBusinessMedicineInfectious disease (medical specialty)OutbreakInternal medicineDiseaseInhalation and Respiratory Drug DeliveryCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research